Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PIM2 | Q9P1W9 | 16/20 | 0.44 |
| ▸ | PIM1 | P11309 | 5/20 | 0.44 |
| ▸ | PIM3 | Q86V86 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18259439 | 1.00 | MAPT (0.46) | MAPTALDH1A1LMNAPIM2PIM1 | |
| SCHEMBL17254425 | 0.81 | MAPT (0.43) | MAPTALDH1A1LMNAPIM2PIM1 | |
| SCHEMBL15875738 | 0.81 | MAPT (0.43) | MAPTALDH1A1LMNAPIM2PIM1 | |
| SCHEMBL17254424 | 0.81 | MAPT (0.43) | MAPTALDH1A1LMNAPIM2PIM1 | |
| SCHEMBL15932902 | 0.80 | MAPT (0.43) | MAPTALDH1A1LMNA | |
| SCHEMBL15873409 | 0.79 | MAPT (0.42) | MAPTALDH1A1LMNAPIM2PIM1 | |
| SCHEMBL15873410 | 0.79 | MAPT (0.42) | MAPTALDH1A1LMNAPIM2PIM1 | |
| SCHEMBL15913504 | 0.79 | MAPT (0.42) | MAPTALDH1A1LMNAPIM2PIM1 | |
| SCHEMBL1710224 | 0.79 | MAPT (0.42) | MAPTALDH1A1LMNAPIM2PIM1 | |
| SCHEMBL13734129 | 0.79 | MAPT (0.42) | MAPTALDH1A1LMNAPIM2PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2262802-B1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| WO-2010026122-A1 | HETEROCYCLIC PIM-KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-03-11 | — | — | WO | disclosed |